Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data as of December 31, 2013.
- Issued Share Capital: 5,342,206,696 Ordinary Shares of 25p each.
- Treasury Shares: 487,433,663 Ordinary Shares.
- Total Voting Rights: 4,854,773,033.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data or discussion of changes in capital structure is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share counts and does not contain forward-looking statements or risk analysis.
Investor Verification Checklist
- Verify the total number of voting rights (4,854,773,033) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of treasury shares held (487,433,663) to calculate the correct denominator for ownership percentage calculations.
- Note that this filing does not contain financial performance data; refer to the company's Form 20-F or annual report for revenue and profit metrics.